ALLRAllarity TherapeuticsFinished
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
Metastatic Breast Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Apr 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 20 (final count)
- Started
- Jun 20, 2018
- Main results expected
- Apr 1, 2024
- Fully finished
- Aug 1, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Anti-tumour efficacy after treatment with 600 mg 2X-121 as single oral agent in a 21-days cycle in mBC patients selected by the 2X-121 DRP
Measured over: one year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-04-01, no fading
Raw record changes
- none yet
Trial ID NCT03562832 · record last updated 2025-01-23 · checked 2026-11-09 15:47 UTC